In this article
Eli Lilly
on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study.
The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks. The results support the pharmaceutical giant’s efforts to bring next-generation treatments to the blockbuster weight loss drug market, and solidify its dominance in the segment.
The data bolsters Eli Lilly’s chances of bringing a strong competitor to the red-hot amylin space, in particular. Many industry analysts view so-called amylin analogs as the next wave of obesity treatments that could serve as an alternative or complementary option to existing injections targeting gut hormone GLP-1.
